Travel prepared with the phone numbers and addresses of local pharmacies, hospitals, and urgent care centers.
Site Search
The Cystic Fibrosis Foundation is a people-centered organization that offers a unifying mission that guides our work, generous benefits, and rewarding career opportunities across multiple disciplines.
This purchase order agreement is designed for vendors that wish to agree to our standard terms and conditions and receive approved payment more quickly.
Por medio de los ensayos clínicos, se han obtenido logros increíbles en el tratamiento de la fibrosis quística (FQ). Gracias a estas investigaciones y a los voluntarios que se han ofrecido como participantes en los estudios, actualmente hay medicinas y tratamientos que han agregado mañanas, y que hacen que la vida con FQ sea mejor para miles de personas. Estos voluntarios y quienes los apoyan en los ensayos clínicos son pioneros que abren caminos hacia los tratamientos nuevos.
The Cystic Fibrosis Foundation offers a broad range of funding opportunities to support academic and industry investigators to pursue research on topics relevant to cystic fibrosis. Each application undergoes a rigorous scientific review process before funding is allocated.
This program is intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat cystic fibrosis with an emphasis on advancing CFTR gene repair and replacement approaches.
The Robert J. Beall Award, created in 2015, recognizes members of the CF scientific community whose work embodies and carries on Beall's innovative, determined and collaborative spirit in driving advances in CF research.
Our corporate champions are an important part of our progress — with corporate supporters by our side, we continue to advance our goal — to make CF stand for Cure Found.
Scientists around the world agree that global innovation is needed to address the shortage of effective antibiotics. Our Infection Research Initiative supports much-needed research and development, but new policies are needed to promote a sustainable, robust antibiotics pipeline and a marketplace that rewards innovation.